Status:

COMPLETED

Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder

Lead Sponsor:

Goethe University

Collaborating Sponsors:

Heidelberg University

Radboud University Medical Center

Conditions:

Attention-Deficit / Hyperactivity Disorder

Depression

Eligibility:

All Genders

14-45 years

Phase:

PHASE2

Brief Summary

Depression and obesity are very common among adolescents and young adults with attention-deficit/ hyperactivity disorder (ADHD). However, intervention programmes to prevent these comorbid disorders ra...

Detailed Description

The risk for comorbid major depressive disorder and obesity is increased in adolescents and adults with attention-deficit/ hyperactivity disorder (ADHD), and adolescent ADHD predicts adults major depr...

Eligibility Criteria

Inclusion

  • Diagnosis of ADHD according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
  • Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise)

Exclusion

  • Intelligence Quotient (IQ) below 75
  • Any severe (comorbid) psychiatric disorder with necessary additional psychopharmaco or daycare/ inpatient therapy beyond treatment as usual
  • Severe medical/ neurological condition not allowing bright light therapy or exercise
  • History of epilepsy
  • Use of antipsychotics, antiepileptic or photosensitising medication
  • Substance abuse/ dependency

Key Trial Info

Start Date :

March 13 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2020

Estimated Enrollment :

207 Patients enrolled

Trial Details

Trial ID

NCT03371810

Start Date

March 13 2017

End Date

August 31 2020

Last Update

October 19 2020

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Goethe University Hospital Frankfurt, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, and Department of Psychiatry, Psychosomatic Medicine and Psychotherapy

Frankfurt am Main, Germany

2

Radboud University Medical Centre, Karakter Child and Adolescent Psychiatry, and Department of Psychiatry

Nijmegen, Netherlands

3

Vall d'Hebron Research Institute, Group of Psychiatry, Mental Health and Addiction

Barcelona, Spain

4

King's College London, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience

London, United Kingdom

Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder | DecenTrialz